Heptares targets GPCR opportunities with Imperial College London

Innovent & Incyte strike Chinese licensing deal
Credit: Shutterstock.com/ WAYHOME studio

Heptares Therapeutics, a subsidiary of Japan’s Sosei Group Corporation, has entered into a new drug research and development collaboration with Imperial College London.

The multi-year collaboration brings together complementary teams seeking to rapidly advance drug discovery and translational research focused on multiple new and existing G protein-coupled receptor (GPCR) disease target opportunities associated with the gastro-intestinal (GI) tract.

The collaboration aims to leverage the significant recent progress made in understanding how GPCRs in the GI tract can be modulated and will support the application of Heptares structure-based approaches to develop novel treatments for GI disorders such as inflammatory bowel disease.

Malcolm Weir, Chief R&D Officer of Sosei and Heptares, said: “This collaboration with Imperial College London builds on existing GPCR programmes implicated in immune disorders and GI function and we are excited by the potential it offers to support the identification and translation of new therapies for patients with GI diseases.”

Professor Jonathan Weber, Acting Dean of the Faculty of Medicine at Imperial College London, said: “Breakthroughs in this field could ultimately help to the improve quality of life for patients living with inflammatory bowel disease, which affects more than half a million people in the UK alone.”

Heptares will fund and support various programmes of work in terms of target discovery and validation and will be responsible for the progression and commercialisation of any compounds resulting from the collaboration.

The collaboration will also support ongoing discovery and development programmes at Sosei/Heptares.